European trial of 'pharmed' anti-HIV monoclonal delayed by costly regulatory process.
Human tests of a potent antibody against HIV have been delayed by up to a year because of wrangling over the application to run a clinical trial in Europe, Nature has learned.
The consortium behind the project, which uses genetically modified (GM) tobacco plants to make the monoclonal antibody 2G12, now hopes to make its application in June. If approved, it will be the first academic-led clinical trial in Europe of a drug produced in a GM plant.
The Pharma-Planta consortium of 28 academic institutions and 4 small companies was awarded €12 million (US$15.6 million) in 2004 by the European Commission to carry out a five-year project to develop plant-derived pharmaceuticals for HIV, rabies and tuberculosis. One of the project's goals is to help improve the regulations that govern the production of drugs in plants, a potentially cheaper and more efficient technique than conventional manufacturing methods.
The EMEA is blocking developments in this area.
Internationally, only a handful of clinical trials of such drugs are under way, and there are currently no plant-pharmed drugs on the market. Scientists hope that improving the regulations will help to stimulate 'pharming' research in Europe. "Establishing regulation at an early stage is critical for new technologies," says Julian Ma, a molecular immunologist at St George's Hospital Medical School, University of London, UK, and leader of the consortium.
In 2006, the team approached the European Medicines Agency (EMEA), which grants permission for marketing medicinal products in Europe, to discuss their project. "No one in Europe had made any decisions about molecular pharming, and the EMEA needed to develop overarching guidelines so that there is uniformity across Europe," Ma says.
But the group soon hit a roadblock. The EMEA insisted that any further meetings and discussions would be classed as formal scientific advice sessions, which at the time they provided for a fee of €35,000. "For an academic consortium that is publicly funded, this fee is astronomical and unaffordable," says Ma. The EMEA's scientific advice is sold to prospective applicants seeking marketing approval for a product, to help them ensure they meet the agency's safety and quality requirements. That advice does not guarantee that applications will be successful.
In contrast, the Medicines and Healthcare products Regulatory Agency (MHRA), the UK body responsible for ensuring the quality and safety of medicines and devices, charges up to about £4,600 (US$6,700) for similar advice, whereas the US Food and Drug Administration levies no charge.
Although the EMEA provides a 90% discount for small companies, it has no such policy for universities. After negotiating with the consortium, the EMEA agreed in 2008 to grant a 50% discount — on an increased advice fee of €75,500, which came into effect on 1 April this year.
The researchers chose not to pay the fee, and focused on developing guidelines with the European Food Safety Authority on risk assessment of drugs produced by GM plants, which the authority expects to publish in the next few months. The consortium also sought scientific advice from the MHRA, to which they now intend to submit their clinical-trial application.
The EMEA did not answer Nature's specific questions about their interactions with Pharma-Planta, but confirmed in a statement that although "there are no specific fee reductions for universities", universities could submit a request for a fee reduction which will be considered and granted "in exceptional circumstances".
Since Pharma-Planta approached the EMEA, the agency has developed new pharming guidelines, which came into effect in February 2009. Unlike previous regulations, these account for the fact that the conditions for growing drugs in plants are intrinsically variable, and so the same standards of drug manufacture expected of cell-culture and fermentation systems cannot apply. But university researchers still face the EMEA's fees if they want advice on pharming projects, which Ma believes is a significant barrier to translating future academic research in the area.
Marc van Montagu, the president of the European Federation of Biotechnology, says it is "essential" that the EMEA reduces its fee for universities. "The EMEA is blocking developments in this area with their exorbitant bill," he says.
See Editorial, page 946
About this article
Cite this article
Gilbert, N. Fees delay pharmed drug. Nature 458, 951 (2009). https://doi.org/10.1038/458951a